These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7875107)

  • 21. Cognitive function, aging, and ethical decisions: recognizing change.
    Yellowitz JA
    Dent Clin North Am; 2005 Apr; 49(2):389-410. PubMed ID: 15755412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people.
    den Heijer T; Geerlings MI; Hoebeek FE; Hofman A; Koudstaal PJ; Breteler MM
    Arch Gen Psychiatry; 2006 Jan; 63(1):57-62. PubMed ID: 16389197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is new in degenerative dementia disorders?
    Jellinger KA
    Wien Klin Wochenschr; 1999 Sep; 111(17):682-704. PubMed ID: 10526393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive correlates of leukoaraiosis in the early stages of Alzheimer's disease.
    Tsiskaridze A; Shakarishvili R; Janelidze M; Vashadze T; Chikhladze M
    Funct Neurol; 1998; 13(1):17-25. PubMed ID: 9584871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines for addressing ethical and legal issues in Alzheimer disease research: a position paper. National Institute on Aging.
    High DM; Whitehouse PJ; Post SG; Berg L
    Alzheimer Dis Assoc Disord; 1994; 8 Suppl 4():66-74. PubMed ID: 7695858
    [No Abstract]   [Full Text] [Related]  

  • 27. Memory problems in dementia: adaptation and coping strategies and psychosocial treatments.
    Dröes RM; van der Roest HG; van Mierlo L; Meiland FJ
    Expert Rev Neurother; 2011 Dec; 11(12):1769-81; quiz 1782. PubMed ID: 22091600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical development of a drug for brain aging. Current limitations and future prospects].
    Zerbini O; Recchia G; Fabbri L
    Clin Ter; 1990 Mar; 132(6 Suppl):451-5. PubMed ID: 2140969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ethical problems in biomedical research with cognitively impaired elderly patients].
    Helmchen H; Lauter H
    Nervenarzt; 1995 Mar; 66(3):231-8. PubMed ID: 7753249
    [No Abstract]   [Full Text] [Related]  

  • 30. [Guidelines and practice aspects of conducting clinical trials in schizophrenia].
    Waterreus F
    Encephale; 1994; 20(6):719-23. PubMed ID: 7875106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic target for cognition enhancers: diagnosis and clinical phenomenology.
    Allain H; Boyer P; Kossmann L; Lépine JP; Kanowski S
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():49-51. PubMed ID: 2186412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The complexes of degenerative dementias: an evolution from disease to spectrum].
    Robles A
    Neurologia; 2009; 24(6):399-418. PubMed ID: 19798607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ethics and clinical drug trials].
    Villeneuve A
    Encephale; 1990; 16(4):281-2. PubMed ID: 2209483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls.
    Sunderland T; Tariot PN; Mueller EA; Murphy DL; Weingartner H; Cohen RM
    Psychopharmacol Bull; 1985; 21(3):676-9. PubMed ID: 3898182
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical trials in cognitive impairment in the elderly.
    Forette F; Panisset M; Boller F
    Aging (Milano); 1992 Sep; 4(3):239-50. PubMed ID: 1420408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Methodology and legitimacy of French clinical trials in primary chemoprevention of cancers. The point of view of the National Federation of French cancer centers].
    Eisinger F; Maraninchi D; Philip T
    Bull Cancer; 1995 Jul; 82 Suppl 3():232s-236s. PubMed ID: 7492838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fullerenes C60, antiamyloid action, the brain and cognitive processes].
    Podol'skiĭ IIa; Poddubnaia ZA; Godukhin OV
    Biofizika; 2010; 55(1):88-94. PubMed ID: 20184146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anesthesia and the old brain.
    Tang J; Eckenhoff MF; Eckenhoff RG
    Anesth Analg; 2010 Feb; 110(2):421-6. PubMed ID: 19820235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the affective and cognitive effects of a drug: theoretical and methodological considerations.
    Jouvent R
    Arch Gerontol Geriatr Suppl; 1989; 1():165-72. PubMed ID: 2667541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Problems in the search for cognition enhancers.
    Hollister LE
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():33-6. PubMed ID: 2186410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.